Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Irritation and Phototoxicity Study of KX01 Ointment 1% in Japanese Healthy Male Subjects
jRCT2031210434Phase 1Completed
- Sponsor
- PharmaEssentia
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirbanibulin in actinic keratosis (AK), sponsored by PharmaEssentia. Primary endpoint: Safety and tolerability (adverse events and local skin reactions). Started Nov 2021; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on jRCT2031210434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210434.